Skip to main
VYGR

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics is positioned favorably due to its innovative TRACER platform, which is expected to generate revenue streams from collaborations that are advancing to clinical trials in the 2030s. The company's data on VY1706, demonstrating a significant reduction in tau messenger RNA and protein in non-human primates, underscores the potential for durable efficacy with lower liver exposure compared to existing AAV9 therapies. Additionally, recent preclinical studies highlight the NeuroShuttle's ability to maintain central nervous system exposure for an extended duration, suggesting both enhanced therapeutic durability and safety advantages, thereby enhancing the optimistic outlook for Voyager's future growth in the gene therapy market.

Bears say

Voyager Therapeutics has faced significant financial challenges, characterized by a high burn rate and limited cash reserves, which could hinder its ability to fund ongoing research and development activities necessary for advancing its gene therapy programs. Additionally, the company's pipeline, despite its innovative approach to treating severe neurological diseases, has encountered setbacks in clinical trials, raising concerns about the viability and market potential of its AAV-based gene therapies. Furthermore, uncertainties regarding regulatory approvals and the competitive landscape in the gene therapy sector add further risk to Voyager Therapeutics's financial outlook, contributing to a negative assessment of its overall stock performance.

Voyager Therapeutics (VYGR) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 5 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.